Novartis completes first trial of its H1N1 vaccine, says only single dose needed
This article was originally published in Scrip
Executive Summary
Novartis's adjuvanted pandemic H1N1 vaccine Celtura induces sufficient protection with one dose, says the company after completing its first pilot trial of the vaccine.